Editas Medicine Q3 Earnings: Surpasses Revenue Estimates, Shares Up 94.5% YTD

Editas Medicine (EDIT) reported a Q3 loss of $0.28 per share, beating revenue estimates of $7.54 million, a 365.62% increase YoY. The company's shares have added 94.5% since the beginning of the year, compared to the S&P 500's 14.4% gain. The Zacks Rank is #3 (Hold) for the stock, indicating expected performance in line with the market in the near future.